DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...

DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...